Q: Would appreciate your thoughts on these 3. Thanks as always!
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Health Canada approved a drug for GUD & partner Initially price went to $6.60 but ended down 0.03 @ $6.47. Please comment Txs for u usual great services & views
Q: It's been awhile since you commented Fronsac stock. Last earnings looks very good, they mostly rent to gaz stations, fast foods and some grocery stores. Can you comment earnings?
Also, what is your point of view about HLS Therapeutics considering Vascepa?
Thanks 5i!!!
Also, what is your point of view about HLS Therapeutics considering Vascepa?
Thanks 5i!!!
Q: Retired dividend-income investor. Sitting on 6% cash. Looking to add to healthcare exposure in my portfolio. Do you still prefer LIFE over HHL? Would you buy now or would you wait until after the USA election? Thanks...Steve
Q: Hi guys,
I was wondering if you could give a few added thoughts on Veeva, prior to their report on Tuesday. You have said that it is one of your favourite US growth stories, and it has undergone a large 2020 rally already, and some recent range bound movement.
Not knowing more that what I have read here and from reviewing charting, it looks like they have gone through periods of surges and plateaus over the years.
Would you expect some manner of growth announcements or earnings surprise on Tuesday that creates a new growth driver, or are you more of the opinion that there will be some developments in the weeks or months ahead?
Thanks in advance.
I was wondering if you could give a few added thoughts on Veeva, prior to their report on Tuesday. You have said that it is one of your favourite US growth stories, and it has undergone a large 2020 rally already, and some recent range bound movement.
Not knowing more that what I have read here and from reviewing charting, it looks like they have gone through periods of surges and plateaus over the years.
Would you expect some manner of growth announcements or earnings surprise on Tuesday that creates a new growth driver, or are you more of the opinion that there will be some developments in the weeks or months ahead?
Thanks in advance.
Q: Medical Facilities seems to be attracting some attention with modest price increase and increased volume. Would you throw a bit of fun money at it or wait for it to accelerate.
Q: IRTC has had a strong move up this year. What is the reason for the recent momentum and is the share price justified at level.
Q: Does Knight Therapeutics have any connections with Astra Zeneca?
Q: Hi,
DOC: I am looking at cloud md as a speculative growth buy. It is in the same space as WELL and recently closed an acquisition. Financials expected end of month. (comments on anticipated results appreciated) I know it is early days but I think it has potential. Any insights on the potential for this sector generally and the company in particular are much appreciated.. As always thanks for the services you provide.
DOC: I am looking at cloud md as a speculative growth buy. It is in the same space as WELL and recently closed an acquisition. Financials expected end of month. (comments on anticipated results appreciated) I know it is early days but I think it has potential. Any insights on the potential for this sector generally and the company in particular are much appreciated.. As always thanks for the services you provide.
Q: Good day guys:
Opinion of this name please .. is it a buy?
Thx
Mark
Opinion of this name please .. is it a buy?
Thx
Mark
Q: WELL is on an unbelievable run. What do you see as the end game for this company in 2-3 years? A tuck in acquisition for a larger company or a successful standalone?
Q: I have held GUD for years, with very little growth. I am thinking of selling and buying WELL. Which of these stocks do you believe will have better growth and which do you consider less of a risk. Thank you
Q: The price of BNTX has been languishing to $68 since the stock offer at $93 per share in the July. Please help me to understand the reasons of the decline if any. Thank you very much. Bill.
Q: Hi folks, can please get update on your thoughts on Neptune Wellness....into cannabis but also couple of Covid 19 products. Just posted Q2/20 results which showed good growth in revenue & gross profit QoQ, but loss of $11M. Would U rate the stock a buy,hold,sell...or avoid. Thanks as always, jb
Q: In the WELL conference call the CEO made reference to this US company in the same space. Do you know if ONEM is a disciplined capital allocator. Or do they just acquire assets, issue a ton of shares/debt and really not the move the per share earnings needle? Does ONEM look like a good investment?
Q: The only reason they beat with .13 is because they had a "net gain of financial instruments measured at fair value" of $16,499. Last Q, they had a loss.
This number is the reason why it was .13 and not negative.
How valid is this and should this not to be taken out and adjusted to a lower EPS?
Thanks
This number is the reason why it was .13 and not negative.
How valid is this and should this not to be taken out and adjusted to a lower EPS?
Thanks
Q: You said we expect $50.76 mln and EPS of -$0.03 from GUD.
They made a big acquisition which has long closed and we are not
seeing the benefits on the top and bottom lines.
What use is it to hold GUD?
They made a big acquisition which has long closed and we are not
seeing the benefits on the top and bottom lines.
What use is it to hold GUD?
Q: please comment on recent Q results of SIS.Is it time to add my 3.5% pos.Txs for u usual great services& views
Q: I'm trying to get a handle on VMD's valuation; the equity has fallen sharply in the face of what appear to be outstanding results and expressions of continuing responsiveness by management with respect to their prospects. Yet the market seems to be pricing the company as a one trick (Covid 19) exploitive pony. Or perhaps not? And is the overhang from prior days and the accompanying critique still valid? Thank you for your consideration.
Q: I would like your opinion on Centene and Merck? Is valuation good? can you suggest any other US healthcare companies? Do you anticipate growth in this area?
thanks
thanks